Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

(European Society for Medical Oncology) Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to study results presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news